Third Rock launches Tango with $55M

Third Rock Ventures launched Tango Therapeutics Inc. (Cambridge, Mass.) with a tranched $55 million series A round. The firm is the newco's sole investor. Details of the tranches are undisclosed.

The biotech is using a CRISPR-based target discovery platform to develop compounds against novel targets that induce synthetic lethality in cancer cells with specific genomic defects. Synthetic lethality is a phenomenon in which genomic defects that are not lethal individually become lethal when combined. ...